DNA blood test–guided treatment before rectal cancer surgery
Part of Cancer, Digestive system clinical trials.
This trial uses a special DNA blood test (circulating tumor DNA) to help guide chemotherapy and radiation before surgery for locally advanced rectal cancer. It aims to improve outcomes by tailoring treatment based on the DNA signals from the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- Your cancer is rectal adenocarcinoma, confirmed on pathology (lab tissue testing).
- Your tumor is close enough to the anus: the lower edge is less than 12 cm from the anal opening.
- Your cancer stage is locally advanced (cT3–4 N0M0 or any T with lymph nodes involved, with no distant spread like M1).
- You have not had treatment yet (no radiation, chemotherapy, or surgery for this cancer).
- Your general health is good enough for treatment (ECOG 0–2) and your kidneys/liver can tolerate chemotherapy and radiation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks a blood test called circulating tumor DNA to help choose the best time and approach for chemotherapy after colon cancer surgery. It aims to reduce recurrence by identifying people who may benefit from treatment based on changes seen in the blood.
This trial studies a blood test (called ctDNA) in people with colon cancer that has spread to the liver and is being removed with curative surgery. The goal is to see how the blood test can help with planning and improving treatment after surgery.
This trial uses a personalized blood test (ctDNA-MRD) to see how well neoadjuvant therapy works for rectal cancer. If you have stage II or III rectal cancer that can be surgically removed, this study might help guide your treatment.
This study looks at whether a blood test that finds tumor DNA can help doctors choose the best treatment for rectal cancer, possibly allowing some patients to avoid surgery. It tests different chemotherapy and radiation combinations to see if the cancer disappears completely.
This study uses a simple blood test (called MRD) after surgery to see if any tiny bits of cancer DNA are left. It helps doctors decide whether extra chemotherapy is needed or if it can be safely skipped, and it may reduce unnecessary side effects.
This trial tests whether checking for tumor DNA in your blood after surgery can help decide if you need additional chemotherapy. If the test finds cancer DNA, you may get chemo to lower the risk of the cancer coming back.
Hear when a new Circulating Tumor DNA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.